KCT0000576招募中未知
The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Monotherapy Compared to Glimepiride in Patients With Type 2 Diabetes Mellitus
Eli Lilly Korea0 个研究点目标入组 789 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 789
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 18(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1.Type 2 diabetes mellitus
- •2.OAM-naive or have been taking OAM monotherapy for at least 3 months
- •3.Glycosylated Hemoglobin (HbA1c) value of =7.0% to =10.5% for OAM-naive participant or =6.5% to =10.0% for participant taking OAM monotherapy
- •4.Adult men or adult non-pregnant, non-breastfeeding women
- •5.Stable weight (±5%) =3 months prior to screening
- •6.Body Mass Index (BMI) of =19.0 to =35.0 kilograms/square meter (kg/m^2)
排除标准
- •1.Have type 1 diabetes mellitus
- •2.Have previously been treated with a glucagon-like peptide-1 (GLP-1) receptor agonist, GLP-1 analog, or any other incretin mimetic during the 3 months before screening
- •3.Are currently taking dipeptidylpeptidase-IV (DPP-IV) inhibitor and thiazolidinediones (TZD) during the 3 months before screening
- •4.Have gastric emptying abnormality
- •5.Have cardiac disorder defined as unstable angina, myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention, heart failure, arrhythmia, transient ischemic attack, or stroke
- •6.Have poorly controlled hypertension (systolic blood pressure above 160 millimeter of mercury [mmHg] or diastolic blood pressure above 95 mmHg)
- •7.Impaired liver function
- •8.Impaired kidney function
- •9.Have history of chronic pancreatitis or acute pancreatitis
- •10.Have a serum calcitonin =20 picogram/milliliter (pg/mL)
- •11.Have a personal or family history of medullary C-cell hyperplasia, focal hyperplasia, carcinoma or multiple endocrine neoplasia type 2 (MEN 2)
研究者
相似试验
招募中
不适用
A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes MellitusEndocrine, nutritional and metabolic diseaseKCT0000614Eli Lilly Korea789
进行中（未招募）
1 期
Research study to look at how well the drug concizumab works in your body if you have haemophiliaHaemophilia AHaemophilia A with inhibitorsHaemophilia BHaemophilia B with inhibitorsMedDRA version: 20.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850MedDRA version: 20.0Level: LLTClassification code 10053751Term: Hemophilia A with anti factor VIIISystem Organ Class: 100000004850MedDRA version: 20.0Level: LLTClassification code 10018939Term: Haemophilia B (Factor IX)System Organ Class: 100000004850MedDRA version: 20.0Level: LLTClassification code 10053752Term: Hemophilia B with anti factor IXSystem Organ Class: 100000004850EUCTR2019-002641-37-NLovo Nordisk A/S80
进行中（未招募）
1 期
Research study to look at how well the drug concizumab works in your body if you have haemophiliaHaemophilia AHaemophilia A with inhibitorsHaemophilia BHaemophilia B with inhibitorsMedDRA version: 20.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850MedDRA version: 20.0Level: LLTClassification code 10018939Term: Haemophilia B (Factor IX)System Organ Class: 100000004850MedDRA version: 20.0Level: LLTClassification code 10053752Term: Hemophilia B with anti factor IXSystem Organ Class: 100000004850MedDRA version: 20.0Level: LLTClassification code 10053751Term: Hemophilia A with anti factor VIIISystem Organ Class: 100000004850EUCTR2019-002641-37-SEovo Nordisk A/S80
进行中（未招募）
不适用
Effectiveness of a once weekly subcutaneous sc epoetin beta treatment in hemodialysis patients.Renal anemia in hemodialysis patientsMedDRA version: 6.1Level: PTClassification code 10058116EUCTR2004-000983-29-ITROCHE700
进行中（未招募）
不适用
Effectiveness of a once weekly subcutaneous epoetin beta treatment in hemodialysis patients. - Alfa2BetaRenal anemia in hemodialysis patientsMedDRA version: 7.1Classification code 10058116EUCTR2004-000983-29-SEF. Hoffmann-La Roche Ltd.700